Polygalacin D | Cytiva思拓凡-Whatman滤纸滤膜滤器

天然产物糖类和糖苷 Saccharides and Glycosides

Polygalacin D 纯度: 99.30%

Polygalacin D (PGD) 是从桔梗 Platycodon grandiflorum 中分离的具有抗癌和抗增殖特性的生物活性化合物。 Polygalacin D 抑制 IAP 蛋白家族的表达，包括存活蛋白，cIAP-1 和 cIAP-2 蛋白，并通过抑制 GSK3β，Akt 的磷酸化和PI3K 的表达来阻断 PI3K/Akt 途径。Polygalacin D 通过 PI3K/Akt 途径诱导凋亡 (apoptosis)。

Polygalacin D Chemical Structure

CAS No. : 66663-91-0

规格	价格	是否有货
1 mg	￥1520	In-stock
5 mg	￥4570	In-stock
10 mg		询价
50 mg		询价

* Please select Quantity before adding items.

Polygalacin D 相关产品

•相关化合物库:

Natural Product Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Natural Product Library
Anti-Cancer Compound Library
Glycoside Compound Library
Medicine Food Homology Compound Library
Terpenoids Library
Traditional Chinese Medicine Monomer Library

生物活性

Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum (Jacq.) with anticancer and anti-proliferative properties. PGD suppresses the expression of the IAP family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis^[1]

IC₅₀ & Target

IC50: IAP^[1]

体外研究
(In Vitro)

Polygalacin D (0-40 µM; 48 hours) inhibits cell proliferation with IC₅₀s of 26.49 µM in the A549 cells and 20.52 µM in the H460 cells^[1].
Polygalacin D (0-20 µM; 48 hours) increases the proportion of early and late apoptotic cells, and nuclear condensation is observed in A549 and H460 cells^[1].
Polygalacin D (0-20 µM; 48 hours) may exerts its apoptotic effects by regulating the apoptotic proteins and the IAP family of proteins in A549 and H460 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	A549 and H460 cancer cell lines
Concentration:	10 µM, 20 µM, 40µM
Incubation Time:	48 hours
Result:	Inhibited the proliferation of NSCLC cell lines.

Apoptosis Analysis^[1]

Cell Line:	A549 and H460 cancer cell lines
Concentration:	10 µM, 20 µM
Incubation Time:	48 hours
Result:	Induced apoptosis of NSCLC cell lines.

Western Blot Analysis^[1]

Cell Line:	A549 and H460 cancer cell lines
Concentration:	10 µM, 20 µM
Incubation Time:	48 hours
Result:	Decreased survivin, c-IAP-1 and c-IAP-2 expression.

分子量

1209.32

Formula

C₅₇H₉₂O₂₇

CAS 号

66663-91-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : 100 mg/mL (82.69 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.8269 mL	4.1346 mL	8.2691 mL
5 mM	0.1654 mL	0.8269 mL	1.6538 mL
10 mM	0.0827 mL	0.4135 mL	0.8269 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.07 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.07 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.07 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。

参考文献

[1]. Seo YS, et al. Polygalacin D induces apoptosis and cell cycle arrest via the PI3K/Akt pathway in non-small cell lung cancer. Oncol Rep. 2018 Apr;39(4):1702-1710.